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Background: The toll of tuberculous meningitis (TBM) in both 
mortality and disability is considerable, but advancements in 
rehabilitation have the potential to improve the functional abilities 
and the quality of survivors’ lives. However, the typical phenotype of 
neurocognitive impairment in TBM survivors remains unstudied in 
HIV-predominant populations in sub-Saharan Africa. 
Methods: We tested 36 survivors of TBM in Uganda with a 
comprehensive battery of neurocognitive assessments at 8 and 24 
weeks after diagnosis, and compared results to a representative 
cohort of HIV-uninfected Ugandans. 
Results: While participants had a broad range of impairments at eight 
weeks, there was marked improvement by 24 weeks, when a 
phenotype of impairment including deficits in motor functioning, 
verbal learning and memory, processing speed, and executive 
function emerged. These deficits were present despite good clinician-
rated functional status. The majority (23/27, 85%) had evidence of 
moderate to severe depression at week 8, and at week 24 (18/24, 
75%). 
Conclusion: These findings highlight the need for more 
comprehensive neurocognitive assessment in the survivors of TBM, 
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and further investment in and study of rehabilitation, including 
management of depression, to improve long-term outcomes in this 
population.
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Introduction
Tuberculous meningitis (TBM) continues to incur unaccept-
ably high mortality, especially in people living with HIV, in 
whom it can exceed 50%1,2. The persistence of neurologic 
sequelae in those who survive has been long-recognized, and 
can include major neurologic deficits such as hemiplegia and 
blindness, as well as more subtle cognitive changes such as 
memory or psychiatric problems3,4. The various neurologic 
sequelae have been reported to affect a third to a half of 
survivors in some series1,2. These long-term neurological com-
plications are attributed to hydrocephalus5, decreased grey 
matter volume6, and stroke, which may occur in as many as 
57% of patients7,8.
The most commonly employed assessments for long-term mor-
bidity in TBM are the modified Rankin Scale or Barthel Index, 
with recent meta-analyses reporting some physical disability 
in 32% of TBM survivors, using these tools1. While the impor-
tance of severe disability is recognized, and often an endpoint 
in TBM clinical trials9, these broad measures can miss 
the more subtle neurocognitive changes in TBM patients that 
can still impact overall wellbeing and economic output10. 
Two Indian cohort studies used the Mini Mental Status Exam 
and found cognitive impairment in over half of survivors at 
six months and one year after TBM diagnosis11,12. Compre-
hensive neuropsychological testing using the Wechsler Adult 
Intelligence Scale in 17 TBM patients in Taiwan showed 
impairment in multiple domains including working mem-
ory and verbal comprehension6. However, these studies in 
HIV-negative populations may not be representative of 
TB-HIV coinfection, as HIV, both independently and in con-
junction with TB, contributes to neurocognitive impairment13,14; 
yet, TBM in HIV-infected persons is less inflammatory15. 
Given recent findings of variability in reliability of cognitive 
assessments across different regional and cultural settings16, 
it is essential that neurocognitive assessments are modified and 
standardized to local norms, as has been successfully applied 
in past studies of neurocognitive outcomes after cryptococcal 
meningitis17,18. Comprehensive neuropsychological testing has 
never been reported after TBM in an HIV-positive population 
or in sub-Saharan Africa. Furthermore, despite evidence of 
increased risk of mental illness in childhood survivors of 
TBM19, the burden of depression in adult survivors of TBM is 
unknown.
Given the prevalence of disability in TBM survivors, further 
understanding of rehabilitation options is necessary. In 2017, 
the World Health Organization (WHO) identified rehabilitation 
as an increasing unmet need to address disability in low and 
middle income countries, and called for strengthening of these 
systems20. In Uganda, availability of physiotherapy remains 
limited, and is often restricted to those with higher socioeco-
nomic status and education21. Neurorehabilitation has emerged 
as a specialized form of rehabilitation incorporating physi-
otherapy as well as occupational, speech, and psychiatric ther-
apy, to target the potential for brain recovery in neurological 
diseases such as stroke and multiple sclerosis22. Groups in 
India and West Africa have investigated telemedicine strate-
gies for the rehabilitation of survivors of stroke, TBM, and 
other neurologic illnesses to overcome implementation barriers 
that exist in resource-limited settings23,24.
To better target neurorehabilitation resources, a clearer pheno-
type of the neurocognitive and functional impairment in TBM 
is necessary. In this nested prospective cohort study, we 
assessed detailed neurocognitive function, alongside depression 
and functional status, in Ugandan clinical trial participants 
who survived TB meningitis. To describe the cognitive deficits 
associated with TBM and their improvement over the first 6 
months of recovery, tests were repeated at 8 and 24 weeks, 
and compared with a representative healthy control population.
Methods
Population and setting
Patients were enrolled in this prospective cohort from within 
the “High dose oral and intravenous rifampicin for improved 
survival from adult tuberculous meningitis” (RIFT) study, a 
phase 2 open-label randomized trial (ISRCTN42218549)25. 
Patients were enrolled in the parent trial between January 
14 and December 17, 2019, at Kiruddu National Referral 
Hospital in Kampala, Uganda and Mbarara Regional Refer-
ral Hospital in Mbarara, Uganda, based on detection of TB 
in the cerebrospinal fluid (CSF) by Xpert MTB/RIF Ultra 
(Cepheid, Sunnyvale, CA)26, or presentation compatible with 
TBM (CSF:plasma glucose ratio <50% or CSF glucose 
<65 mg/dL), coupled with TBM treatment planned. Exclusion 
criteria and study drug administration details are provided 
in the published trial protocol27. We recorded baseline clinical 
data, CSF results, and demographics at initial presentation. 
Adjunctive corticosteroids were administered to all patients 
and antiretroviral therapy (ART)-naïve individuals initiated 
ART after completion of the intensive phase of TB treatment 
(week 8), in accordance with Ugandan guidelines (tenofovir/
lamivudine/dolutegravir as first-line). HIV-positive participants 
also received cotrimoxazole prophylaxis.
We enrolled participants into this sub-study assessing neu-
rocognitive and functional outcomes from the Kampala site 
eight weeks after their enrollment in the parent trial. We 
included those who survived the initial hospitalization and 
presented for their week eight post-randomization clinic 
follow-up visit. We excluded patients whose meningitis was later 
confirmed to be due to a non-TB etiology.
Procedures
At week 8 and 24 visits, patients’ clinical status was recorded, 
as was their modified Rankin score and Karnofsky perform-
ance score, clinician-determined functional status measures. 
They were screened for depression using the patient health 
questionnaire (PHQ)-9 instrument, which ranges from 1 to 27 
and has been validated in multiple countries in sub-Saharan 
Africa with a cutoff of 10 for moderate or severe depression28,29. 
We used a secondary cutoff of 15 to account for possible 
overlap in physical symptoms with TBM illness. As part 
of the visit, participants received a standardized battery of 
neurocognitive tests in either English or Luganda performed by 
a trained study nurse. The battery of tests evaluates ten 
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neuropsychological and motor domains, and has been validated 
in sub-Saharan African populations and performed in Uganda 
on survivors of cryptococcal disease17,30. The WHO-University 
of California-Los Angeles Auditory Verbal Learning Test 
(WHO-UCLA AVLT) assesses verbal learning and memory31, 
Digit Span Forward and Backward assesses attention and 
working memory32, Semantic Verbal Fluency assesses lan-
guage fluency33, Timed Gait assesses gross motor function34, 
Grooved Pegboard (average of both hands) assesses fine motor 
function35, Finger Tapping (of the dominant hand) assesses 
motor speed36, Symbol Digit Modality assesses processing 
speed and concentration37, Color Trails 1 assesses process-
ing speed and attention, and Color Trails 2 assesses executive 
function38, (Table 1).
Statistical analyses
Raw scores on each test were standardized to duration of 
education (<7 years, 7 to 12 years, and >12 years) and age 
(greater or less than 30 years), matched to HIV-negative 
Ugandan controls (data collected as part of a prior neuro-
cognitive study39,40) to create education- and age-adjusted 
Z-scores. To generate a global measure of neurocognitive func-
tion across all domains, a quantitative neurocognitive per-
formance Z-score (QNPZ-8) was calculated as the mean of 
eight individual Z-scores: Symbol Digit, WHO-UCLA 
AVLT immediate and delayed recall, Verbal Fluency, Color 
trails 1 and 2, Finger Tapping, and Grooved Pegboard. We 
defined neurocognitive impairment as one standard deviation 
below the HIV-negative reference mean (corresponding to a 
Z-score of -1) and severe impairment as two standard devia-
tions (Z-score < -2). Participants were permitted to skip tests 
if they started but were unable to complete it due to visual dif-
ficulties, fatigue, or physical limitations. Skipped tests were 
assigned Z-scores equal to the mean of the TBM cohort minus 
two standard deviations. All analyses were run on STATA 
version 15 (StataCorp, College Station, TX).
Ethical considerations
Written informed consent was obtained from participants 
or their caregiver. The parent trial and this sub-study were 
approved by the Research Ethics Committees of LSHTM, UK, 
Mulago Hospital, Uganda National Council of Science and 
Technology, and Uganda National Drug Authority. An inde-




Of 56 patients enrolled in the parent trial at Kampala, 37 sur-
vived and remained at eight weeks follow-up to be considered 
Table 1. Neuropsychological test battery and neurocognitive domains evaluated.
Test Test Description Cognitive Domains
WHO-UCLA AVLT-Total*
Subjects are asked to recall a list of words. The test is similar to the Rey 
Auditory Verbal Learning test, however words have been selected to be 




Similar to WHO-UCLA AVLT, but subjects are asked to recall the same list of 
words in a delayed recall phase Verbal memory
Digit Span Forward and 
Backward
Subjects are given a series of digits of increasing length and are asked to 
repeat them in forward or backward order
Attention, Working 
memory
Semantic Verbal Fluency Subjects are given 60 seconds to produce as many words as possible within a specific category such as ‘animals’ Language fluency (Verbal)
Symbol Digit Modality Subjects are asked to match geometric figures to numbers as quickly as possible over 90 seconds using a visual reference.
Speed of information 
processing, Concentration
Color Trails 1
Subjects connect encircled numbers scattered on a page in sequence during 
a set amount of time. This test is similar to the Trail Making Test but has 
been formulated to minimize cultural bias by not using any letters or written 
instructions
Speed of information 
processing, Attention
Color Trails 2
Similar to The Color Trails 1 but each number is printed in two different colors, 
and subjects are asked to maintain the numerical sequence while alternating 
colors
Executive function
Timed Gait The time for subjects to walk out and back 10 meters is recorded Gross motor
Grooved Pegboard
Subjects are timed while placing pegs which each have a key along one side 
in holes in various orientations in a pegboard with either their dominant or 
non-dominant hand
Fine motor
Finger tapping Subjects tap as rapidly as possible using the index finger on a specially adapted tapper for five 10-second trials Motor speed
WHO-ULCA AVLT = World Health Organization-University of California-Los Angeles Auditory Verbal Learning test
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for enrollment in this study (Figure 1). The 19 not considered 
for enrollment either did not survive to week 8 (n=14), were 
withdrawn from the parent trial during the initial hospitaliza-
tion (n=3), or were unable to present to their week 8 visit and 
later died (n=2). We enrolled 36 patients into the neurocogni-
tive study after excluding one who had an alternate etiology 
of meningitis. Of the 36, 28 were reassessed at week 24 (n=6 
died, n=2 declined assessment at week 24). 
Demographics and clinical data from the initial hospitaliza-
tion are presented in Table 2. The cohort was relatively young 
(median age 35). Overall, 42% (15/36) had less than 7 years 
of education, 39% (n=14) had seven to 12 years of educa-
tion, and 19% (n=8) had more than 12 years of education. 
Overall, 94% (34/36) were HIV-positive, and 44% (16/36) 
had microbiological-confirmed TBM. Due to low numbers in 
each experimental treatment group, and lack of statistically 
significant difference in the major neurocognitive and func-
tional measures (QNPZ-8, modified Rankin Scale), neurocog-
nitive data is described for the cohort as a whole rather than 
by randomized treatment group from the parent trial.
Week 8 neurocognitive assessment
At eight weeks, 11 patients had at least moderate disabil-
ity with a modified Rankin Scale score greater than or equal 
to 3 (median cohort score = 2, IQR 1-3), and 66% (19/29) of 
patients had Karnofsky scores <80, indicating inability to carry 
on normal activity (Table 3).
At week 8, 86% (31/36) of patients had impaired cogni-
tive function (QNPZ-8 lower than -1), and 53% (19/36) had 
severe impairment (QNPZ-8 lower than -2). The mean QNPZ-8 
score was -2.51 (standard deviation (±SD) ±1.43) representing 
2.51 standard deviations (i.e. Z-score) below the population 
mean for HIV-negative Ugandans, adjusted for age and edu-
cation. At eight weeks, impairment was nonspecific as all 
component assessments of the QNPZ-8 demonstrated cogni-
tive impairment (Z-score < -1) on the cohort-level. Specific 
domains with severe impairment included executive function 
(color trails 2 assessment: -4.93, SD±3.20); verbal learning 
(AVLT-Total: - 2.93, SD±1.66); verbal memory (AVLT-Recall: 
-3.21, SD±2.66); and speed of information processing (color 
trails 1 assessment: -2.20, SD±2.31) (Figure 2). While gross 
motor performance does not contribute to QNPZ-8, gross motor 
performance as assessed by timed gait was severely impaired, 
with a mean Z-score of -7.89 (SD±3.40).
Week 24 neurocognitive assessment
At week 24, three patients had at least moderate disability 
(median modified Rankin = 0, IQR 0-1), and 19% (5/26) of 
patients had a Karnofsky score <80 (Table 3).
At week 24, 61% (17/28) of patients had impaired cognitive 
function, and 25% (7/28) had severe impairment (Figure 3). 
Mean QNPZ-8 at 24 weeks was -1.62 (SD ±1.29). Amongst 
the 28 patients tested at both time points, QNPZ-8 improved 
from a mean of -2.39 (SD ±1.52) to -1.62 (SD ±1.29). The 
Figure 1. Enrollment in this nested sub-study from the parent randomized RIFT trial.
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Table 2. Baseline results in persons with TBM.
Characteristics at Diagnosis
Age, years 35 (29-37)
Women 18 (50%)
Education <7 years 
                    7–12 years 





Receiving ART (of HIV-positive) 12 (35%)
CD4 count, cells/µL 111 (43-272)
CD4 count <200 cells/µL 19 (61%)
Microbiologically-confirmed TBM 16 (44%)
Trial Arm: Standard of Care 
        High dose oral rifampin 




TBM severity: MRC grade       1 
                                                  2 




Glasgow Coma Scale score 14 (12-14)
CSF White Blood Cell Count, cells/µL 35 (<5-125)
CSF Protein, mg/dL 128 (94-177)
CSF Glucose, mg/dL 41 (21-68)
Serum Sodium, mEq/L 130 (126-136)
Values are medians with interquartile range (IQR) or N (%).
ART: antiretroviral therapy, TBM: Tuberculous meningitis, MRC: 
medical research council grade, CSF: cerebrospinal fluid.
Table 3. Week 8 and 24 neurocognitive and functional 
outcomes in persons with tuberculosis meningitis.
Week 8 Week 24
modified Rankin Scale > 2 11 (31%) 3 (10%)
Karnofsky Functional Status Score < 80 19 (66%) 5 (19%)
PHQ-9 Depression Score ≥ 10 23 (85%) 18 (75%)
PHQ-9 Depression Score ≥ 15 19 (70%) 14 (58%)
QNPZ-8 Neurocognitive <-1 Z-score 31 (86%) 17 (61%)
QNPZ-8 Neurocognitive <-2 Z-score 19 (53%) 7 (25%)
Abbreviations: PHQ-9: patient health questionnaire 9
most improved domains over these 16 weeks were fine motor 
(grooved pegboard, Z-score difference = 1.15) which improved 
to the mean of the HIV-negative Ugandan control group, 
and executive function (color trails 2 assessment, Z-score 
difference 1.32) which remained severely impaired (Figure 2). 
Other domains which remained impaired were processing 
speed (color trails 1: -1.32 (SD ±1.66)) (symbol digit modal-
ity: -1.33 (SD ±1.21)), verbal learning (AVLT-total: -1.86 
(SD ±1.65)), verbal memory (AVLT Recall: -2.16 (SD ±2.01)), 
and motor speed (finger tapping: -1.58 (SD ±1.20)). Color 
trails 1 and symbol digit modality also assess concentration 
and attention; however, these domains were judged unimpaired 
based on relatively normal results on tests of concentration and 
attention which do not test processing speed: digit span for-
ward and backward (-0.76 SD ±2.1; -0.14 SD ±2.6 respec-
tively). Timed gait remained severely impaired: mean Z-score 
was -5.11 (SD ±3.69).
Of note, seven patients at eight weeks, and two patients at 
24 weeks were too ill to complete any test and therefore all 
scores including QNPZ-8 are imputed 2 standard deviations 
below the cohort mean. In a parallel analysis excluding these 
patients (see Underlying data), mean scores were slightly 
improved but relative differences between domains were similar 
in both populations.
Depression screening
Moderate and severe depression, as defined by a PHQ-9 
score ≥10 was present in a majority of the cohort (23/27 (85%) 
able to complete the questionnaire) at week 8. At week 24, 
rates of moderate and severe depression were somewhat 
lower (75%; 18/24), but still constituted a large majority of 
the cohort. Even with a higher cutoff (≥15), the majority 
screened positive for depression at both time points (Table 3). 
Among the 21 who completed the questionnaire at both time 
points, moderate and severe depression was present in 17 (81%) 
at week 8, and 15 (71%) at week 24.
Discussion
In this prospective study of 36 survivors of TBM in Uganda, 
we have reaffirmed the high degree of early functional dis-
ability present, demonstrated neurocognitive and functional 
improvement between two and six months, and described a 
phenotype of neurocognitive impairment predominantly in 
executive functioning, information processing speed, and 
verbal learning and memory. This phenotype is less apparent 
at eight weeks, when patients are often still recovering from 
their acute illness and are broadly impaired, but by 24 weeks 
becomes clear as some neurocognitive domains approach pop-
ulation norms while others remained impaired. Notably, at 
this time many patients were judged as clinically well and 
without significant disability (based on the modified Rankin 
Scale) by the study doctor, but there remained significant 
neurocognitive deficits that were identified on comprehensive 
neurocognitive testing. Longer follow-up is necessary to deter-
mine the durability of this impairment, and whether longer-term 
recovery is likely.
Many of the deficits identified were motor-related, including 
gross motor (timed gait), fine motor (grooved pegboard), and 
motor speed (finger tapping). Of the more explicitly cognitive 
domains, verbal learning and memory, processing speed, and 
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Figure 2. Impairment in neurocognitive domains at eight and 24 weeks in survivors of TBM. Mean cohort Z-scores in each 
neurocognitive assessment and the summary score (QNPZ-8) at both time points show improvement in most domains. A Z-score <-1 
signifies impairment, and a Z-score <-2 signifies severe impairment. Error bars represent standard error. DSF: Digit Span Forward, DSB: Digit 
Span Backward, AVLT: WHO-UCLA Audio Verbal Learning Test Total, AVLTR: WHO-UCLA Audio Verbal Learning Test Recall, SDM: Symbol Digit 
Modality, GPB: grooved pegboard, QNPZ-8: Quantitative neurologic performance on eight modalities.
Figure 3. Proportions of the cohort that are no longer impaired in each assessment at week 24. Bars approaching 1 signify few 
participants with impairment in that domain. Majorities of the cohort have impairment in AVLT, AVLTR, SDM, Finger tapping, Color Trails 1, 
Color Trails 2, Timed Gait, and the summary score (QNPZ-8). Impairment on any given assessment is defined as a Z-score <-1. DSF: Digit 
Span Forward, DSB: Digit Span Backward, AVLT: WHO-UCLA Audio Verbal Learning Test Total, AVLTR: WHO-UCLA Audio Verbal Learning Test 
Recall, SDM: Symbol Digit Modality, GPB: grooved pegboard, QNPZ-8: Quantitative neurologic performance on 8 modalities.
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executive function were especially affected. The deficits 
described mirror many of those found in a prior Taiwanese 
study (which did not test motor domains), where TBM sur-
vivors had significant deficits in processing speed (digit 
symbol), verbal comprehension (similarities), working memory 
(letter-number sequencing), and additionally, perceptual organi-
zation (block design, matrix reasoning)6. While this suggests 
potential generalizability of TBM neurocognitive outcomes 
between HIV-positive and HIV-negative populations, further 
study is necessary.
Reflecting the epidemiology of TBM in Uganda41, a majority of 
the cohort was HIV-positive and among those, a majority had 
a baseline CD4 T cell count <200 cells/µL, putting them at 
significant risk of HIV-associated dementia42. Dissecting the 
neurocognitive impacts of HIV infection and TBM is inher-
ently difficult, and current definitions of HIV-associated demen-
tia exclude patients with central nervous system opportunistic 
infections like TBM43. The typical profile of neurocognitive 
impairment in HIV-associated dementia includes deficits in 
verbal learning and memory, executive functioning, attention, 
and processing speed40,44. The deficits we described in TBM 
survivors in memory, executive functioning, and processing 
speed overlap this profile, although the additional deficits in 
gross motor domains, and relatively good performance in tests 
of attention not relying on speed, are notable. When the 
same battery of neurocognitive tests was administered to an 
HIV-positive cohort in Uganda40, participants were impaired in 
verbal learning, gross motor, and executive function, but to a 
lesser degree than in this TBM cohort at 24 weeks (comparable 
Z-scores presented17). This suggests neurocognitive impair-
ment after TBM beyond what would be expected from HIV 
alone. ART improves symptoms of HIV-associated dementia30, 
and 24 week testing on TBM survivors in our study (16 weeks 
after ART initiation) showed significant but far from com-
plete improvement from baseline. Longer follow-up and evi-
dence of immune recovery is necessary to better understand 
the contribution of HIV to the neurocognitive impairment 
after TBM.
We found a high prevalence of depression in survivors of 
TBM at both eight and 24 weeks. This is consistent with find-
ings of high rates of depression in South African children 
with TBM19. Interestingly, the rates of depression in this study 
are higher than in adult survivors of cryptococcal meningi-
tis in Uganda (73% at one month in a 2010–2013 cohort, 
62% in a 2015–2017 cohort)17,45. While there has been 
little study of the relationship between TBM and depres-
sion, the pathophysiology and treatment of TBM in our 
cohort involves HIV infection, inflammation, neurologic 
injury, and glucocorticoids, all of which are also associated 
with depression46–50. IL-6, known to play an important role in 
depression51–53, including inhibiting the serotonin pathway, is 
significantly associated with the severity of TBM54. Cognitive 
impairment is a known symptom of depression55, so some of 
the cognitive impairment seen in the cohort could be 
attributable to depression. As prior psychiatric illness was not 
assessed, we cannot determine whether premorbid depression 
may have also contributed to risk of advanced HIV and TBM. 
Given the association between depression and HIV-induced 
immunosuppression14, it is notable that unlike the significant 
improvement in depression reported after ART initiation in 
survivors of cryptococcal meningitis17,56, high rates of 
depression persisted in our cohort at six months, well after 
ART was initiated. Immunologic differences in the response 
to cryptococcal meningitis and TBM54, known to be impor-
tant in the development and persistence of depression57,58, may 
partly explain this disparity. Differences between TBM and 
cryptococcal meningitis disease severity could further explain 
the difference in depressive symptoms, with TBM having 
higher rates of altered mental status while hospitalized45,59–61, 
strokes7,8,62, and persistent neurologic deficits. A compre-
hensive treatment of depression is essential to improve out-
comes in TBM, and should be incorporated into follow-up and 
rehabilitation protocols.
The improvement in both motor and cognitive domains over 
six months is remarkable even without formal rehabilitation, 
but further recovery potential remains unknown. Given the 
predominance of motor impairment, physiotherapy could pro-
vide significant benefits, and deserves further study. More 
specialized rehabilitation practices might show benefit in the 
recovery from deficits in processing speed, executive func-
tion, and memory. Rehabilitation protocols designed for 
stroke survivors, which are the most available worldwide22,24, 
could be effective for TBM given that there is also a high 
prevalence of motor deficits, depression, and cognitive defi-
cits (especially executive function and processing speed), 
although the exact phenotype of cognitive deficits differs 
depending on stroke location63,64. This population (median age 
35 years) are in the most economically active period of life 
and thus rehabilitation may prove to be cost-effective. Further 
investment in local physiotherapy is essential in sub-Saharan 
Africa, but increasing experience with telemedicine provides 
an alternate method of care delivery23,24. Novel approaches, 
including brain-training video games, might be applica-
ble for recovery from TBM as they have shown promise in 
improving working memory and processing speed in other 
populations65,66.
Strengths of this study include standardization of results to a 
locally representative cohort and detailed neurocognitive pro-
filing at two time-points; limitations include the small cohort 
size and lack of follow up beyond 6 months. Larger studies 
will be necessary to investigate baseline risk factors for poor 
neurocognitive outcome.
Comprehensive neurocognitive testing of TBM survivors in 
sub-Saharan Africa is feasible. There is significant neurocogni-
tive recovery between 2 and 6 months, but significant deficits 
remain in motor domains, as well as processing speed, verbal 
learning, and executive function. These findings highlight the 
need for neurorehabilitation and management of depression 
in TBM survivors.
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Data availability
Underlying data
Repository name: Data Compass, https://doi.org/10.17037/
DATA.0000237267
This project contains the following underlying data:
-    Individual baseline results
-    Individual clinical statuses at weeks 8 and 24
-    Modified Rankin, Karnofsky performance,and PHQ-9 
scores
-    Individual raw scores for each test in the battery of 
neurocognitive tests
-    Individual Z-scores on the neurocognitive tests
Data are available under the terms of the Data Sharing Agree-
ment. Due to ethical considerations surrounding the sensi-
tivity of the data in a vulnerable population, study consents 
limited the access to underlying data from this study. How-
ever, controlled access to the data posted in the above reposi-
tory is permitted after signing of the agreement and IRB 
approval. Readers interested in the data can learn more by 
completing the application form on the Data Compass reposi-
tory, or by contacting the LSHTM Research Data Manage-
ment Service at researchdatamanagement@lshtm.ac.uk with 
the dataset DOI.
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Quinn, et al highlight the knowledge gap regarding neurocognitive and psychiatric outcomes in 
people with HIV (PWH) who survive TB meningitis (TBM) overall and in sub-Saharan Africa in 
particular and set out to determine these outcomes in a group of PWH TBM survivors in Uganda. 
They found nearly uniform neurocognitive impairment at 8 weeks, which improved but remained 
substantial at 24 weeks. In particular, verbal learning and memory, processing speed, and 
executive function were impaired as well as multiple domains of motor function. The authors also 
found high rates very high rates of depression at 8 weeks, and this did not change significantly at 
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literature. However, there are important methodological and analytical decisions that were made 
which need to be further explained and/or reconsidered in order to further strengthen the paper. 
Finally, I believe a more nuanced consideration of the limitations of the study is also needed. 
Specifically:
The authors state that the goal of the study was to understand post-TBM depression and 
cognitive outcomes in PWH living in sub-Saharan Africa. As such, it is surprising to me that 
the two HIV-uninfected participants were included in the study. These patients are likely to 
be quite different than those with HIV co-infection and increase the heterogeneity of the 
population and data obtained. Given that they represent such a small proportion of the 
study cohort, I would strongly consider excluding them from the analysis or, at minimum, 
provide a strong justification for why they should remain. 
 
1. 
Please expand more on how the possibility that the treatment received in the trial may have 
contributed to neurocognitive and/or depression outcomes was assessed. It may also be 
prudent to list the possibility that this was not able to be completely accounted for in the 
analysis due to small sample sizes in each treatment group as a possible limitation. 
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Please provide greater detail about the demographics of HIV-uninfected controls used for 3. 
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neurocognitive norms. Was the language of administration similar? Were education levels 
distributed somewhat similarly? This is important in understanding the validity of the 
normative data used for the study cohort and may also be a limitation of the study. 
 
Please justify the decision to include patients who were too sick to complete the analyses in 
the neurocognitive outcomes but not the depression outcomes. Do the authors really think 
including these patients is representative of the typical neurocognitive deficits after TBM? At 




It appears there is a significant number of participants with missing data on functional 
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The authors state that the goal of the study was to understand post-TBM depression and 
cognitive outcomes in PWH living in sub-Saharan Africa. As such, it is surprising to me that 
the two HIV-uninfected participants were included in the study. These patients are likely to 
be quite different than those with HIV co-infection and increase the heterogeneity of the 
population and data obtained. Given that they represent such a small proportion of the 
study cohort, I would strongly consider excluding them from the analysis or, at minimum, 
provide a strong justification for why they should remain. You bring up a very important 
point about our study population, and a manner in which the manuscript suffered 
from imprecise wording. In designing the study, we endeavored to enroll a 
population that was representative of the TB Meningitis burden in Uganda. Past 
studies of neurocognitive outcomes of TBM have enrolled patients from southern 
and southeast Asia, and we wanted to ensure patients in Sub-Saharan Africa were 
represented in this literature. This Ugandan TBM population is largely, but not 
entirely, an HIV-positive population. However, as you state, our title and other high-
level descriptions of the study refer to the cohort as "HIV-positive" which is 
misleading. We will therefore change our language to reflect that this is a "primarily 
HIV-positive cohort" and our goal was moreso to reflect the population of TBM 
survivors in Uganda. 
 
1. 
Please expand more on how the possibility that the treatment received in the trial may 
have contributed to neurocognitive and/or depression outcomes was assessed. It may also 
be prudent to list the possibility that this was not able to be completely accounted for in 
the analysis due to small sample sizes in each treatment group as a possible limitation. 
You are correct in wondering how the trial treatment could have impacted 
neurocognitive outcomes in survivors, and it is a question that we intend to study 
further in the future. This study was not powered to answer this question, and the 
numbers in each of the treatment groups that survived to neurocognitive assessment 
follow-up is too low to meaningfully comment on the differential impact of the trial 
treatments. However, in these small groups, there did not appear to be any 
significant difference in the summary neurocognitive score between the treatment 
groups. We will ensure that this data is provided in the revised manuscript (it is 
currently present in the extended data that is available), and comment on this 
accordingly as a limitation of the manuscript. 
 
2. 
Please provide greater detail about the demographics of HIV-uninfected controls used for 
neurocognitive norms. Was the language of administration similar? Were education levels 
distributed somewhat similarly? This is important in understanding the validity of the 
normative data used for the study cohort and may also be a limitation of the study. The 
HIV-negative control participants are cohorted by age and education in the same 
groups as our study population to allow for norming of the study data. The tests were 
also performed in Luganda and English according to participant preference for both 
the controls and study population. We will provide more complete demographics 
beyond this in the revised manuscript. 
 
3. 
Please justify the decision to include patients who were too sick to complete the analyses in 
the neurocognitive outcomes but not the depression outcomes. Do the authors really think 
including these patients is representative of the typical neurocognitive deficits after 
4. 
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TBM? At a minimum, it would be great to present more detail about how results differed 
when excluding them. The decision to include participants too sick to complete the 
neurocognitive assessment was one of the major challenges in designing this study; 
while both options (to include or not to include) had drawbacks, I will provide our 
rationale here and comment further in the revised manuscript. Our intended 
population was survivors of TB meningitis -- many of these survivors are 
unfortunately very functionally impaired and remain with a significant burden of 
chronic symptoms from their TBM. To exclude these patients would be to represent 
TBM as a less morbid disease than it in fact is. It is true that the imputed values for 
the neurocognitive assessments in these patients aren't particularly meaningful on 
an individual level, and do not further our goal of demonstrating a typical phenotype 
of impairment in TBM. However, they do serve to accurately represent the degree of 
neurocognitive impairment frequently present in survivors of TBM. We did perform a 
sensitivity analysis showing that inclusion of these patients did not importantly 
impact the neurocognitive domains affected. We will be sure to add this data to the 
revised manuscript and explain this limitation further. Furthermore, we hope for this 
study to contribute to a standardized format allowing cross-comparison for future 
studies of neurocognitive impairment in TBM, which may have goals of investigating 
risk factors for impairment -- in which case inclusion of these more impaired patients 
is essential.  
 
It appears there is a significant number of participants with missing data on functional 
outcome measures at 8 weeks. Can this be explained? Thank you for noting this. This 
Karnofsky functional score were missing in patients deemed too impaired to 
complete neurocognitive assessment; however, as those scores are in fact available, 
they will be added to the revised manuscript. 
5. 
Thank you again for your many constructive comments. We intend to submit a revised 
manuscript after receiving a second review so as to respond to comments from both 
reviewers. I am hopeful that the revised manuscript appropriately addresses your 
concerns.  
Sincerely, 
Carson Quinn on behalf of the authors  
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